Royalty Pharma (RPRX) is anticipated to report increased earnings in the next release, leading to an upgrade of its rating by Moody's and maintaining a stable outlook. The company's Q2 2025 dividend has been declared at $0.22 per share, with the payment to be made on June 10. This has led to a jump in its RS Rating to 92. Key investors like PDT Partners, Tudor Investment Corp, and Walleye Capital have bought a significant number of shares.
Despite Jim Cramer's disappointment, Royalty Pharma is performing well this year. The company's stock has been increasing in value since announcing their Q1 2025 financial results and a $3B buyback plan. This prosperous performance is reflected in the increased consensus PT from brokerages, set at $42.50.
Contributing to this bullish performance, the company is investing in strategic opportunities, including a $125M RYTELO deal. Nonetheless, the company's current financial outlook is ambiguous and needs to be monitored closely to maintain this positive momentum.
Royalty Pharma Stocks News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Sat, 03 May 2025 08:22:06 GMT - Rating 7 - Innovation -4 - Information 9 - Rumor -3
